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Abstract: This paper reviews information on the 
co-morbidity of mental disorders among 
individuals with psychoactive drug or alcohol use 
problems. Findings from key European and 
non-European studies are presented, along with 
an overview of the information on co-morbidity 
reported to the EMCDDA by EU Member States 
and Norway in the last six years. Substance use 
and mental disorders may interact in a number of 
ways, and they may be influenced by overlapping 
factors, such as early exposure to stress. 
Diagnosing co-morbidity in substance users is 
often complicated by methodological issues. 
Clinical and epidemiological studies have shown 
that the occurrence of co-morbid mental 
disorders can be high among individuals with 
psychoactive substance use problems. Co-
morbidity particularly affects vulnerable groups, 
such as prisoners. While studies on the 
prevalence of co-morbidity have been carried out 
in other parts of the world, few have been 
conducted in Europe. The European studies 
presented here show a wide variation in 
prevalence levels, which may reflect 
methodological limitations, including the lack of 
harmonised European reporting on co-morbidity. 
Suggestions are made to stimulate the 
accumulation of knowledge and the 
comparability of information in this area in order 
to improve the evidence base available to 
policymakers. 
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diagnosis as the ‘co-occurrence in the same individual of a 
psychoactive substance use disorder and another psychiatric 
disorder’ (WHO, 2010). Less commonly, the term refers to the 
co-occurrence of two psychiatric disorders not involving 
psychoactive substance use, or the co-occurrence of two 
diagnosable substance use disorders (WHO, 2008).
Information on psychiatric co-morbidity and its prevalence in 
Europe, although limited, is now increasing as several 
countries have started to study the topic. As a result, some 
information on psychiatric co-morbidity is now available for all 
EU Member States. However, large-scale epidemiological 
studies on the prevalence of psychiatric co-morbidity, such as 
those that have been conducted in Australia and the United 
States, are rare in Europe. Two European studies deserve 
special mention. The first is a large-scale study published in 
2009 by Baldacchino and colleagues, which will be discussed 
in the current paper. The other notable body of European 
research is that currently being pursued by Torrens and 
colleagues in Barcelona (see Torrens, 2013). Despite the 
growing amount of information available, our understanding of 
co-morbidity is restricted by the lack of harmonisation 
between countries in data collection and reporting 
(Baldacchino et al., 2009; Torrens et al., 2012).
The EMCDDA wishes to stimulate the collection and exchange 
of information on psychiatric co-morbidity across Europe for 
several reasons, including: the likely high prevalence of 
co-morbidity in drug using populations; the apparent 
increasing trend in co-morbidity among drug users; and the 
lack of adequate treatment options targeting those affected by 
co-morbid disorders.
I  What is the relationship between substance use and 
mental health disorders?
The term ‘psychiatric co-morbidity’ does not have any 
implication for the existence of, or the nature of the 
relationship between, substance use and mental health 
disorders, or for the aetiological relationship between the two 
conditions (Hall et al., 2009). Psychiatric co-morbidity, or 
co-morbid mental and substance use disorders, may occur 
concurrently (two disorders are present at the same time) or 
successively (two disorders occur at different times in a 
person’s life); in both cases, the two disorders may or may not 
be causally related (Frisher et al., 2009; Langas et al., 2011).
Research studies show that substance use, withdrawal 
symptoms and dependence may lead to or exacerbate 
psychiatric or psychological symptoms or syndromes. 
Conversely, psychiatric disorders may lead to substance use 
and addiction (Crome, 2006; Torrens et al., 2011). Three 
possible scenarios can be considered:
I Introduction
Clinical and epidemiological studies have shown that the 
frequency of occurrence of co-morbid mental disorders in 
individuals who use alcohol or other psychoactive substances 
can be high (Baldacchino et al., 2009; Kessler et al., 2005). 
While mental disorders are risk factors for substance use 
disorders, the presence of a substance use disorder may 
affect the occurrence of mental disorders. However, 
diagnosing co-morbidity in substance users is often 
complicated by symptom overlap, symptom fluctuations, and 
the limitations of the assessment methods, among other 
methodological issues. Among those with a mental health 
disorder, data from clinical samples indicate that between a 
third and a half will meet the criteria for another mental or 
substance use disorder at some point in their lives (Hall et al., 
2009). Among substance users, the most common mental 
disorders are personality disorders, anxiety and mood 
disorders. While statistics exist for some countries in Europe 
and elsewhere, assessing the overall prevalence of psychiatric 
co-morbidity in the European Union is hampered by the lack of 
agreed criteria to define co-morbid disorders and by the 
scarcity of national studies. This points to a need to develop 
European harmonised research and monitoring instruments 
on the co-occurrence of mental disorders among those with 
substance use problems as a first step towards being able to 
describe this phenomenon at European level.
This paper aims to stimulate discussion and interest at 
European level on psychiatric co-morbidity. It contains a brief 
description of the co-occurrence of substance use and mental 
health disorders in European countries, without claiming to 
provide a complete and comprehensive overview of existing 
information. The paper presents an overview of the 
information on psychiatric co-morbidity, as it is reported in the 
Reitox National reports submitted to the EMCDDA in the last 
six years, together with the main findings from selected 
European and non-European studies.
I What is co-morbidity?
At a general level, the term co-morbidity means the presence 
or coexistence of additional diseases with reference to an 
initial diagnosis or to the index condition that is being 
examined (Baldacchino and Corkery, 2006).
In the field of psychiatry, despite the lack of a full consensus 
on terminology, co-morbidity commonly refers to the co-
occurrence of two or more different mental disorders during a 
period of time; this usually includes substance use and 
another mental health disorder (Evans and Sullivan, 2001). 
Another term extensively used to indicate the co-occurrence 
of mental health and substance use disorders is ‘dual 
diagnosis’. The World Health Organization defines dual 
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•   Psychiatric co-morbidity may have serious consequences 
for morbidity (e.g. infectious diseases) and mortality (e.g. 
suicide).
I Sources of information
This paper reviews the information available in the literature 
on the prevalence of psychiatric co-morbidity in the general 
population and in specific population groups. In addition, it 
presents some epidemiological data from European countries, 
although these are based on a variety of study methods and 
are not intercomparable.
The information presented in this paper is derived primarily 
from two sources: studies from the literature (from Australia, 
Europe and the United States); and data reported by European 
countries to the EMCDDA. The EMCDDA is the European 
Union agency responsible for providing ‘factual, objective, 
reliable and comparable information at European level 
concerning drugs and drug addiction and their consequences’ 
(EC, 2006). To this end, the EMCDDA collects qualitative and 
quantitative data from the 28 EU Member States as well as 
from Norway and Turkey, primarily through yearly Reitox 
National reports on the drug situation.
The National reports include information on health correlates 
of substance use and a specific section on psychiatric 
co-morbidity. This paper’s analysis includes all the Reitox 
National reports on the drug situation in the 28 EU Member 
States (see Table A1 in the Annex), Norway and Turkey from 
2006 to 2011; some of the most recent information from the 
literature on psychiatric co-morbidity is also analysed. 
However, the data are often limited and, because of 
differences in methodology, type of mental health or 
substance use disorder or focus of analysis, are not 
comparable between countries. For these reasons, it has not 
been possible to perform any statistical analysis on the 
available data; information is simply summarised from the 
studies and National reports. Furthermore, it should be borne 
in mind that the National reports are a secondary source of 
information, derived from original research studies that may 
not be readily accessible, and as such do not allow a 
comprehensive picture of co-morbidity among drug users to 
be constructed.
In this paper, the analysis is limited to the co-occurrence of a 
single substance use disorder and a mental health disorder; 
polydrug use is not discussed, as it would require specific 
analysis. The co-occurrence of two mental health problems, 
excluding a substance use disorder, is also not discussed. The 
paper’s scope is influenced by the EMCDDA’s mandate, which 
centres on illicit drugs, and for that reason, the focus is 
primarily on psychiatric co-morbidity when it involves illicit 
•   Drug use may cause users to experience one or more 
symptoms of a mental health disorder, either short-lived 
(e.g. amphetamine-induced psychosis) or triggering an 
underlying long-term mental disorder (e.g. cannabis and 
schizophrenia).
•   Mental disorders may lead to drug use to alleviate the 
symptoms of a mental disorder (e.g. amphetamines used to 
alleviate symptoms of depression).
•   Both the substance use problem and the mental health 
disorder may be caused by overlapping factors: brain 
deficits, genetic vulnerability and early exposure to stress or 
trauma.
It is often difficult to make a clear diagnosis of psychiatric 
co-morbidity. First, the symptoms of drug use and of mental 
health disorders can be hard to distinguish, as some drugs 
may produce the same effects as a mental disorder. Secondly, 
it is often difficult to assess the time span of the two disorders: 
drug use is more often observed in people with mental 
disorders, who may use drugs as a sort of self-medication 
(Hall et al., 2009); alternatively, drug use may trigger a latent 
mental health problem. However, when a professional makes a 
diagnosis of psychiatric co-morbidity, it is important to identify 
(or try to identify) when the first symptoms appeared, what are 
those symptoms and what is their developing process. The 
diagnostic instruments should give more attention to the 
temporal appearance of the symptoms (Torrens, 2008). 
Thirdly, there is lack of validated instruments for the clinical 
diagnosis of psychiatric co-morbidity, and usually the same 
international standard instruments used in the field of mental 
health are used for the diagnosis of psychiatric co-morbidity, 
even if new instruments specifically devised for psychiatric 
co-morbidity are available (Mestre-Pintó et al., 2013; Torrens, 
2006). In addition, the primary area of expertise of the 
professionals who are working with people with psychiatric 
co-morbidity, may influence the main diagnosis (i.e. whether 
they have mainly worked in mental health, or in the drugs field) 
(Baldacchino and Corkery, 2006).
Despite the difficulties in defining and diagnosing psychiatric 
co-morbidity, the following issues are widely accepted in 
research and clinical practice, and should be highlighted when 
discussing the topic (Crome, 2006):
•   The combination of substance use and mental health 
disorders often results in serious social, psychological and 
physical complications.
•   Psychiatric co-morbidity makes a substantial contribution to 
the burden of diseases worldwide, especially among 
vulnerable population groups.
•   People with co-morbid disorders have poorer diagnosis, 
lower access to care and poorer compliance with treatment.
•   The occurrence of a substance use or a mental health 
disorder is often reciprocally interlinked, with one condition 
leading to or exacerbating the other.
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alcohol use disorders increase the risk of subsequently 
developing drug dependence, harmful drug use or both. 
Participants with affective disorders and anxiety disorders 
were found to be at higher risk of harmful drug use and drug 
dependence, and the effects did not vary by the length of time 
the respondents had been exposed to mental disorders (Liang 
et al., 2011).
According to other studies among people using drugs and 
alcohol, the most common mental health disorders are 
depression, anxiety and schizophrenia, but eating disorders, 
post-traumatic stress disorders, attention deficit and 
hyperactivity disorders and memory disorders may also occur. 
Alcohol problems often appear in association with bipolar 
disorders, schizophrenia and personality disorders (Advisory 
Council on the Misuse of Drugs, 2008; Arendt, 2005; Cantwell 
and Scottish Comorbidity Study Group, 2003).
Studies have also explored the most common combinations of 
mental health disorder and type of drug consumed. The 
results of these studies vary, though this may be related to 
differences in methodology, such as in the instruments used 
for the classification of mental health disorders. One study 
found that the most common combinations are between 
anxiety or mood disorders, and alcohol or illicit drug use 
disorders; these are followed by the combinations of conduct 
disorders, antisocial personality disorder and illicit drug use 
disorders (Hall et al., 2009). Studies have found that alcohol 
disorders increase the risk of major depression; ecstasy and 
heroin users present more substance-induced disorders, and 
in particular mood disorders (Torrens, 2011). Differences are 
reported in the prevalence of psychiatric co-morbidity 
according to personal and social characteristics, particularly 
in relation to gender and vulnerable social groups (homeless, 
unemployed, ethnic minorities) (e.g. SAMHSA, 2012).
I Studies on psychiatric co-morbidity in Europe
An overview of the prevalence of psychiatric co-morbidity and 
on the types of mental health and substance use disorders is 
presented below, based on findings of a selection of European 
projects published in the literature and from the Reitox 
National reports provided to the EMCDDA. Data are presented 
here for 28 of the 30 countries reporting to the EMCDDA. It 
should be noted that considerable national variation in the 
nature and quality of the information available makes it 
inadvisable to draw comparisons between countries.
Few studies carried out in Europe have analysed the 
prevalence levels of psychiatric co-morbidity in the general 
population. A recent European project estimated that 43 to 
120 individuals per 100 000 population meet the criteria for a 
diagnosis of psychiatric co-morbidity (alcohol misuse, 
substance misuse, serious — psychotic — mental health 
drugs, rather than alcohol–mental health co-morbidity. 
Tobacco use is not included among the substance use 
patterns. The paper’s focus is on epidemiological data, and not 
on the consequences for public health interventions.
I Prevalence and nature of co-morbidity
I Studies from Australia and the US
Australian and US epidemiological studies have analysed the 
prevalence of psychiatric co-morbidity in different population 
groups. Non-trivial prevalence levels are reported in the 
general population: according to the last US survey on drug 
use and health, 9.2 million adults in the United States (4 % of 
the adult population) met criteria for both a mental illness and 
substance use disorder in the past year (SAMHSA, 2012). 
Studies conducted among substance users and people with 
mental health problems reported higher prevalence levels of 
co-morbidity. The data varied substantially due to differences 
in clinical assessment and study methodologies. The following 
reports from US and Australian studies include both the 
general population and patients admitted to mental health 
and substance use treatment.
The American Epidemiologic Catchment Area Survey found 
that 35 % of the respondents (a sample of around 21 000 
persons aged 18 and older) who reported having ever had a 
mental health disorder, including drug use disorders, had one 
or more additional disorder at some time in their life. Among 
people with a drug use disorder (other than alcohol use) at 
any time in their life, 53 % also reported ever having had 
another mental disorder, and among those with an alcohol 
disorder, 37 % had also had another mental disorder 
(Bourdon et al., 1992).
An Australian study among people with mental health 
problems found that co-morbidity between anxiety, 
depressive and substance use disorders was very common, 
with 30–50 % of those with any mental disorder meeting the 
criteria for another mental or substance use disorder at some 
point in their lives (Hall et al., 2009).
Looking at the type of disorder, results from a US nationally 
representative face-to-face household survey found that the 
disorders with the highest lifetime prevalence among the 
general population were anxiety (29 %), impulse control 
(25 %), mood (21 %) and substance use disorders (15 %) 
(Kessler et al., 2005).
An Australian retrospective cohort study interviewed a total of 
8 841 Australian adults to collect information on mental 
disorders and to investigate whether affective, anxiety and 
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Among those with a mental health disorder, the prevalence of 
psychiatric co-morbidity is high, ranging from 8 % to 52 % 
(Table A1). In a Norwegian study among patients with 
psychotic disorders, lifetime illicit drug use was 44 % higher 
than in the general population, and lifetime use of 
amphetamines and cocaine was reported to be 160 % higher 
than in the general population (Ringen et al., 2008).
When describing prevalence of substance use among people 
with mental health disorders, the substances most frequently 
reported are alcohol, opioids, amphetamines, hypnotics and 
sedatives, and cannabis. However, these findings may be 
influenced by the greater attention paid to those substances 
compared to others when studying mental health disorders.
A number of European studies have been carried out on 
combinations of mental and substance use disorders, but 
caution should be exercised in interpreting the data since the 
studies cannot be directly compared, and different 
instruments have been used for clinical assessment. The most 
common combinations reported in Europe include:
•   alcohol use and depression or anxiety;
•   opioid use and personality or behavioural disorders;
•   cannabis use and schizophrenia;
•   amphetamines use and psychotic disorders.
In studies that have looked at trends in psychiatric co-
morbidity, increases have been reported in the prevalence 
levels over the last 10 years. This might be related to several 
factors, such as more awareness of the co-occurrence of 
substance use and mental health problems, higher prevalence 
of drug use and mental health disorders in the population, 
higher treatment availability, targeting people with a dual 
diagnosis or de-institutionalisation of patients with mental 
health problems (Daly et al., 2007; Crome, 2006).
I  Prisoners: an example  of a vulnerable group
Psychiatric co-morbidity particularly affects vulnerable 
groups, such as young people, people from ethnic minorities, 
prisoners and sex workers. Psychiatric co-morbidity in prison 
settings is a problem affecting a large part of the prison 
population.
A large number of studies have estimated the prevalence of 
mental disorders as well as substance use in prisons, with 
prevalence estimates varying widely. In general, studies on 
the prevalence of mental illnesses in prison show large 
differences between the prison population and the general 
population in severe pathologies such as psychosis and 
problems) in Denmark, Finland, Poland, England and Scotland 
(Baldacchino et al., 2009).
Other studies on the co-occurrence of substance use and 
mental health problems have focused primarily on populations 
that are easily accessible, and in particular either people 
entering treatment for drug use problems or people with 
mental health disorders.
Available information on drug users entering treatment 
indicates that in 14 European countries prevalence levels of 
psychiatric co-morbidity range from 14 % to 54 %, with a 
further three countries reporting that up to 90 % of drug 
treatment entrants present with a co-morbid psychiatric 
disorder (EMCDDA, 2011; Table A1). The wide range may 
depend on variations in the studies’ methods (e.g. population 
sample, settings, type of disorders or substance use disorder 
studied, reference period), differences in diagnostic 
instruments used for clinical assessment, or on actual 
differences in the prevalence of psychiatric co-morbidity 
across countries and populations. In addition, it must be borne 
in mind that the studies reported in this paper represent only a 
sub-set of all existing European studies: essentially those 
selected by the reporting countries augmented by recent 
studies from the literature.
The severity and type of disorders vary depending on the 
individual and the type of drug problem presented; again, 
studies that have looked at those dimensions come from 
different sources and use different methodologies, and are 
therefore not comparable at the European level. Belgium has 
reported that about 54 % of clients entering drug treatment 
had a dual diagnosis, and of these, four-fifths were assessed 
as having a moderate dual diagnosis and the remaining fifth a 
severe dual diagnosis.
The type of co-morbid mental disorder also varies according to 
drug use patterns and individual characteristics. Despite 
methodological differences across countries and studies, 
some commonalities have been found concerning the types of 
mental health disorders among problematic drug users. The 
most frequent disorders reported in European studies 
(EMCDDA, 2011), grouped according to the ICD-10 
classification (ICD-10, 2010), and mainly referring to AXIS I 
and II of the DSM-IV (2010), are:
•   disorders of adult personality and behaviour disorders 
(including antisocial personality disorder);
•   neurotic, stress-related and somatoform disorders 
(including anxiety and panic attacks);
•   mood (affective) disorders (including depression, dysthymia);
•   behavioural and emotional disorders with onset usually 
occurring in childhood and adolescence (including attention 
deficit hyperactivity disorder);
•   schizophrenia, schizotypal and delusional disorders.
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I Limitations
A number of methodological limitations should be considered 
when reading this paper. The first limitation concerns the 
subject of the study — psychiatric co-morbidity — which is 
difficult to diagnose because of symptom overlaps and 
fluctuations.
The symptoms related to drug taking or mental health 
disorders may combine and reinforce each other when they 
appear, making it difficult to distinguish between the two 
disorders (Langas et al., 2011). Furthermore, the symptoms 
related to drug use and those related to a mental health 
disorder can be confused. For example, an opioid user who 
stops using the drug may, in an initial phase, report symptoms 
similar to those of depression, while in fact they are suffering 
from opioid withdrawal; in that case it would be necessary to 
wait between four and eight weeks to make a clear psychiatric 
diagnosis (Havassy et al., 2004).
Methodological limitations also arise due to the clinical 
instruments used for assessment (Crome, 2006). There is a 
lack of validated diagnostic instruments, and different 
international instruments are often used (the most common 
are DSM-IV and ICD-10). DSM-IV distinguishes between 
substance use disorders and substance induced disorders, 
where substance induced disorders refer only to mental 
health disorders that are temporarily caused by substance 
use and must be in excess of the expected effects of the 
substance (Langas et al., 2011). However, it is often difficult 
to make this distinction because of the concurrent use of 
several substances, which may cause different effects, and 
the co-occurrence of several mental health disorders. 
Another difficulty may be related to the fact that in clinical 
practice more attention may be paid to one symptom or to 
another, depending on the main interest or expertise of the 
professional who treats the patient (Baldacchino and 
Corkery, 2006).
Methodological limitations must also be borne in mind when 
considering epidemiological data from different countries 
(Langas et al., 2011). Generally, studies on co-morbidity are 
not comparable, and this is especially so for studies carried 
out in different countries. The lack of comparability is due to 
variations in the following factors (see also Table A1):
•   Study samples: the general population is rarely the studied 
population; more often study samples are patients attending 
drug or mental health services. Between and within the two 
different settings (drug and mental health treatment 
services), there may be differences in the number and 
characteristics of people and treatment services included in 
the studies. Also, studies may vary in focus, with some 
giving more attention to specific population groups (for 
example, prisoners, males or females).
personality disorders, as well as problems such as anxiety 
and depression (Fazel and Baillargeon, 2011; Fazel and 
Danesh, 2002).
A systematic review and meta-analysis of 62 surveys of 
approximately 23 000 prisoners from 12 countries found that 
around 4 % of prisoners had an identified psychotic illness 
(including schizophrenia, schizophreniform disorder, maniac 
episodes, and delusional disorder), 10–12 % had major 
depression (unipolar affective disorder), and 42–65 % had a 
personality disorder (mostly antisocial personality disorder) 
(Fazel and Danesh, 2002). The study suggested that typically 
about one in seven prisoners in ‘western countries’ have a 
psychotic illness or major depression (disorders that might be 
risk factors for suicide), and about one in two male prisoners 
and one in five female prisoners were identified as having 
antisocial personality disorders. These results are supported 
by studies carried out in European countries.
A Spanish study found that 30 % of prisoners had a 
personality disorder, including 12 % with antisocial disorders 
and borderline personality disorder, 3 % with paranoid 
disorders and 2 % narcissistic and schizoid disorders 
(Arroyo and Ortega, 2009). The finding that personality 
disorders are more prevalent among prison populations is in 
agreement with other studies (Rotter et al., 2002). It should 
be noted that this study suggests that all the individuals 
diagnosed with personality disorders were also drug users. 
Differences between male and female prisoners are 
reported in the type and prevalence of psychiatric co-
morbidity (Zlotnick et al., 2008).
In the United Kingdom, the Bradley Report found high levels 
of mental health problems among prisoners and suggested 
that dual diagnosis should be considered as the norm 
(Bradley, 2009).
In Estonia, 25 % of all prisoners were diagnosed with a dual 
diagnosis.
Studies from France suggested that 55 % of incoming 
inmates suffer from psychiatric co-morbidity, including drug 
use and a mental disorder, such as anxiety-depressive and 
addictive disorders, psychoses (Table A1). Rouillon et al. 
(2011) reported that 80 % of male inmates and 70 % of 
female inmates had at least one psychiatric disorder in 
2003–04. The most common problems were: depressive 
syndromes (40 %), generalised anxiety (33 %), traumatic 
neuroses (20 %), agoraphobia (17 %), schizophrenia (7 %), 
and paranoia or chronic hallucinatory psychoses (7 %). 
Multiple disorders were also frequent, primarily mood and 
anxiety disorders (three to four in every ten inmates); anxiety 
disorders and drug or alcohol dependence; mood disorders 
and addiction; anxiety and psychotic disorders (one in every 
five inmates).
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countries only qualitative information is available (literature or 
Reitox National reports). This only allows a general review of 
individual studies to be presented, and it is therefore not 
possible to provide harmonised information on psychiatric 
co-morbidity at the European level.
The EMCDDA therefore aims to stimulate the accumulation of 
knowledge and comparability of information in the area of 
co-morbidity of mental health and substance use disorders. 
This would allow a European level description to be drawn up 
and would provide a better evidence base for European 
policymakers. To achieve this, it is necessary to gather 
harmonised information at country level. It would be also 
beneficial to compare data from different epidemiological 
indicators (e.g. treatment demand and drug-related deaths, 
psychiatric hospital admissions) and to extend the study of 
psychiatric co-morbidity to different time windows (e.g. in a 
lifetime, in the last month) and specific population groups (e.g. 
prisoners, sex workers, travellers, ethnic minorities). Finally, 
the use of large databases that include information on 
substance use and mental health problems, where available at 
national level, would enable a broader and more accurate 
assessment of the extent of psychiatric co-morbidity.
•   Subjects of study: the study’s subject may vary; for instance, 
it could be about generic mental health or drug use 
disorders, or specific mental health problems and substance 
use. The level of specificity may also differ greatly, 
depending on the main focus of the study.
•   Study instruments: this might relate to the survey itself (e.g. 
questionnaires, interviews) or to the instruments used for 
clinical assessment (e.g. ICD-10, DSM-IV).
•   Terminology: there may be variations due to cultural or 
linguistic differences, when the original language is not 
English and it is translated, or due to different theoretical 
approaches.
•   Epidemiological measures: different epidemiological 
measures may be applied.
•   Time references: different measures may have been used 
for the epidemiological study (lifetime, last year or last 
month prevalence) or for the time span considered when the 
prevalence of psychiatric co-morbidity is analysed (co-
occurrence or sequential occurrence of mental health and 
drug use disorder) (Crome, 2006).
The collection of data on psychiatric co-morbidity is not 
harmonised between countries in Europe, and in some 
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I Annex
TABLE A1
Summary of the most recent data reported to the EMCDDA on the co-morbidity of drug use and mental health problems in EU 
Member States and Norway
Country
Prevalence of psychiatric co-
morbidity (year of data collection)
Reference population Type of disorder/notes
Austria 51 % (2010) Drug users in treatment n.a.
Belgium 54 % (2010) Drug users in treatment Type of disorder – n.a.
41 % moderate; 13 % severe
Bulgaria 2–10 % (2008) Drug users in treatment from 
different types of facilities
n.a.
Croatia 21 % (2010) Drug users in treatment Mainly opioid users: 86 % of whom have a 
co-morbid disorder
Personality disorders, 20 %
Behavioural disorders, 23 %
Schizophrenia, 16 % 
Cyprus 5–43 % (2009) Drug users in treatment Depression
Difficulties in concentration
Stress
Czech Republic 7 % (2001–05) Methamphetamine users 
admitted to hospitals
Psychotic disorder
Denmark 11–29 % (2002) Psychiatric patients Schizophrenia
Affective disorders
Stress-related disorders
Personality disorders
Estonia 25 % Prisoners n.a.
Finland >50 % (2010) Drug users in treatment 
(especially misusers of 
buprenorphine)
Depression
France 55 % (2009) Prisoners (incoming inmates) Anxiety
Depression
Germany 28–52 % (2010) Psychiatric patients Anxiety disorders, 23 %
Affective disorders, 19 %
Somatoform disorders, 9 %
Attention deficit hyperactivity disorders, 9 %
Greece 17 % (2010) Drug users in treatment n.a.
Hungary 57 % (2007) Drug users in treatment Boredom
Sadness or slight depression
Anxiety or intensive worrying
Ireland 6 per 100 000 general population 
(2006)
Data recorded at psychiatric 
first admission in psychiatric 
hospitals
Type of disorder – n.a.
Increasing trend from 3 per 100 000 in 1990 to 6 
per 100 000in 2006
Italy 22 % (2007) Drug users in treatment Mainly males
Mean age: 36 years
Opioids and polydrug users
Affective psychoses, 18 %
Neurotic somatic disturbances, 10 %
Schizophrenic psychoses, 7 %
Other disturbances, 7 %
Paranoid state, 1 % 
Latvia 18 % (2009) Drug users in treatment Organic mental disorders, 25 %
Behavioural and emotional disorders, 21 %
Neurotic/stress-related disorders, 17 % 
Lithuania 9 % (2009) Psychiatric patients n.a.
Luxembourg 83 % had previous contacts with 
psychiatric services (2009) 
Drug users in treatment Anxiety
Depression
Neurosis/psychosis
Borderline behaviour
Malta n.a. Patients of dual diagnosis 
clinic
Depression
Paranoid personality disorder
Borderline personality disorder
Narcissistic personality disorder
Netherlands 84 % (2007) Opioid users in methadone 
treatment (202)
Major depression and generalised anxiety 
disorders, 34 %
Psychotic disorder, 39 %
Current psychotic disorder, 9 %
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Country
Prevalence of psychiatric co-
morbidity (year of data collection)
Reference population Type of disorder/notes
Norway 23 % (2010)
20–47 % (2010)
Psychiatric patients
Psychiatric emergency 
patients
n.a.
Poland 8 % (2005) Patients admitted to inpatient 
psychiatric hospitals
n.a.
Portugal 53 % (2005) Long-term street addicts 
undergoing treatment
Depression
Romania 14 % (2009) Drug users in treatment Behavioural and emotional disorder
Slovakia 14 % (2004) Patients of psychiatric 
hospitals
Schizophrenia (in the last years with positive 
correlation with cannabis treatment demand)
Slovenia 3 045 (2009) Hospitalisations related to 
drug, alcohol and mental 
health disorders
n.a.
Spain 13 % (2007) Drug users in treatment Personality disorders
Antisocial disorder and borderline disorder, 12 %
Paranoid disorder, 3 %
Narcissistic and schizoid disorders, 2 %
Sweden 47 % (2002–04) Drug users in treatment Borderline, 18 %
Schizotypal, 12 % 
United Kingdom 
(England)
60–90 % (2002) Substance misusers in 
treatment
Anxiety (32 % female; 17 % male)
Depression (30 % female; 15 % male)
Paranoia (27 % female; 17 % male)
Psychoticism (33 % female; 20 % male)
United Kingdom 
(Scotland)
21 % female; 32 % male
42 % female; 40 % male 
Psychiatric patients
Drug treatment patients
Alcohol and depression
Alcohol and anxiety
Diazepam and anxiety
n.a., information not available.
NB: Because of differences among the studies listed here, such as target populations, subjects, and time references, their results are not intercomparable.
Sources: Data from 2006, 2007, 2008, 2009, 2010, 2011 Reitox National reports and the literature.
EMCDDA PAPERS I Co-morbid substance use and mental disorders in Europe: a review of the data
10 / 12
I  Advisory Council on the Misuse of Drugs (2008), Cannabis: classification and public health, Home 
Office, London.
I  Arendt, M. (2005), ‘Cannabis-induced psychosis and subsequent schizophrenia-spectrum disorders: 
follow-up study of 535 incident cases’, British Journal of Psychiatry 18 (6), pp. 510–15.
I  Arroyo, J. M. and Ortega, E. (2009), ‘Personality disorders amongst inmates as a distorting factor in 
the prison social climate’, Revista Espanola Sanidad Penitenciaria 11, pp. 11–5.
I  Baldacchino, A. and Corkery, J. (2006), Comorbidity: perspective across Europe, ECCAS Monograph 
No. 4, European Collaborating Centres in Addiction Studies, London.
I  Baldacchino, A., Groussard-Escaffre, N., Clancy, C., Lack, C., Sieroslavrska, K. et al. (2009), 
‘Epidemiological issues in comorbidity: lessons learnt from a pan-European ISADORA project’, 
Mental Health and Substance Use: Dual Diagnosis 2 (2), pp. 88–100.
I  Bourdon, K. H., Rae, D. S., Locke, B. Z. et al. (1992), ‘Estimating the prevalence of mental disorders in 
U.S. adults from the Epidemiologic Catchment Area Survey’, Public Health Reports 107, pp. 663–8.
I  Bradley, K. (2009), ‘The Bradley report: Lord Bradley’s review of people with mental health problems 
or learning disabilities in the criminal justice system’ (available at: www.dh.gov.uk).
I  Cantwell, R. and Scottish Comorbidity Study Group (2003), ‘Substance use and schizophrenia: 
effects on symptoms, social functioning and service use’, British Journal of Psychiatry 182, pp. 
324–29.
I  Crome, I. B. (2006), ‘An epidemiological perspective of psychiatry comorbidity and substance 
misuse: the UK experience/example’, in Baldacchino, A. and Corkery, J. (editors), Comorbidity: 
perspective across Europe, ECCAS Monograph No. 4, European Collaborating Centres in Addiction 
Studies, London, pp. 45–60.
I  Daly, A., Walsh, D. and Moran, R. (2007), Activities of Irish psychiatric units and hospitals 2006, 
Health Research Board, Dublin.
I  DSM-IV (2010), Diagnostic and statistical manual of mental disorder, American Psychiatric 
Association, Arlington, VA.
I  EC (European Commission) (2006), ‘Regulation (EC) No. 1920/2006 of the European Parliament and 
of the Council of 12 December 2006 on the European Monitoring Centre for Drugs and Drug 
Addiction (recast)’, Official Journal of the European Union L 371/6, pp. 1–13 (available at: http://
eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:32006R1920:EN:NOT).
I  EMCDDA (European Monitoring Centre for Drugs and Drug Addiction) (2011), Reitox National reports 
2010 (available at: www.emcdda.europa.eu/publications/national-reports).
I  Evans, K. and Sullivan, M. J. (2001), Dual diagnosis: counseling the mentally ill substance abuser, 2nd 
edition, Guilford Press, New York.
I  Fazel, S. and Baillargeon, J. (2011), ‘The health of prisoners’, The Lancet 377, pp. 956–65.
I  Fazel, S. and Danesh, J. (2002), ‘Serious mental disorder in 23,000 prisoners: a systematic review of 
62 surveys’, The Lancet 359, pp. 545–50.
I  Frisher, M., Crome, I., Martino, O. and Croft, P. (2009), ‘Assessing the impact of cannabis use on 
trends in diagnosed schizophrenia in the United Kingdom from 1996 to 2005’, Schizophrenia 
Research 113 (2–3), pp. 123–8.
I  Hall, W., Degenhardt, L. and Teesson, M. (2009), ‘Understanding comorbidity between substance 
use, anxiety and affective disorders: broadening the research base’, Addictive Behaviors 34, 
pp. 526–30.
I  Havassy, B. E., Alvidrez, J. and Owen, K. K. (2004), ‘Comparison of patients with comorbid psychiatric 
and substance use disorders: implications for treatment and service delivery’, American Journal of 
Psychiatry 161, pp. 139–45.
References
EMCDDA PAPERS I Co-morbid substance use and mental disorders in Europe: a review of the data
11 / 12
I  ICD-10 (2010), International statistical classification of diseases and related health problems, 10th 
revision, apps.who.int/classifications/icd10/browse/2010/en (accessed on 20 November 2013).
I  Kessler, R. C., Berglund, R., Demler, O. et al. (2005) ‘Lifetime prevalence and age-of-onset 
distributions of DSM-IV disorders in the National Comorbidity Survey Replication’, Archives of 
General Psychiatry 62, pp. 593–602.
I  Langas, A.-M., Malt, U. and Opjoirdsmoen, S. (2011), ‘Comorbid mental disorder in substance users 
from a single catchment area: a clinical study’, BMC Psychiatry 11, p. 25.
I  Liang, W., Chikritzhs, T. and Lenton, S. (2011), ‘Affective disorders and anxiety disorders predict the 
risk of drug harmful use and dependence’, Addiction 106, pp. 1126–34.
I  Mestre-Pintó, J. I., Domingo-Salvany, A., Martín-Santos, R., Torrens, M. et al. (2013), Dual diagnosis 
screening interview to identify psychiatric comorbidity in substance users: development and 
validation of a brief instrument, European Addiction Research (published ahead of print 1 August 
2013, doi:10.1159/000351519).
I  Ringen, P. A., Melle, I., Birkenaes, A. B., Engh, J. A., Faerden. A. et al. (2008), ‘Illicit drug use in patients 
with psychotic disorders compared with that in the general population: a cross-sectional study’, Acta 
Psychiatrica Scandinavica 117, pp. 133–38.
I  Rotter, M., Way, B., Steinbacher, M., Sawyer, D. and Smith, H. (2002) ‘Personality disorders in prison: 
aren’t they all antisocial?’, Psychiatric Quarterly 73 (4), pp. 337–49.
I  Rouillon, F., Gasquet, I., Garay, R. P. and Lancrenon, S. (2011), ‘Screening for bipolar disorder in 
patients consulting general practitioners in France’, Journal of Affective Disorders 130 (3),  
pp. 492–95.
I  SAMHSA (Substance Abuse and Mental Health Services Administration) (2012), Results from the 
2010 National Survey on drug use and health: mental health findings, www.samhsa.gov/data/
nsduh/2k10MH_Findings/2k10MHResults.htm (accessed on 20 November 2013).
I  Torrens, M. (2008), ‘Patología dual: situación actual y retos de futuro’, Addiciones 20 (4), pp. 315–20.
I  Torrens, M. (2013), Dual pathology, psychiatric comorbidity in addictive disorders, www.imim.es/
programesrecerca/neurociencies/en_manifestacionspsiquiatriques.html (accessed on 20 
November 2013).
I  Torrens, M., Santos, R.-M. and Samet, S. (2006), ‘Importance of clinical diagnosis for comorbidty 
studies in substance use disorders’, Neurotoxicity Research 10 (3–4), pp. 253–61.
I  Torrens, M., Gilchrist, G. and Domingo-Salvany, A. (2011), ‘Psychiatric comorbidity in illicit drug users: 
substance-induced versus independent disorders’, Drug & Alcohol Dependence 113, pp. 147–56.
I  Torrens, M., Rossi, P., Martinez-Riera, R., Martinez-Sanvisens, D. and Bulbena, A. (2012), ‘Psychiatric 
co-morbidity and substance use disorders: treatment in parallel systems or in one integrated 
system?’, Substance Use & Misuse 47, pp. 1005–14.
I  WHO (World Health Organization) (2008), The global burden of disease: 2004 update, World Health 
Organization, Geneva.
I  WHO (2010), Lexicon of alcohol and drug terms published by the World Health Organization, www.
who.int/substance_abuse/terminology/who_lexicon/en/ (accessed on 20 November 2013).
I  Zlotnick, C., Clarke, J. G., Friedmann, P. D. et al. (2008), ‘Gender differences in comorbid disorders 
among offenders in prison substance abuse treatment programs’, Behavioral Sciences and the Law 
26, pp. 403–12.
EMCDDA PAPERS I Co-morbid substance use and mental disorders in Europe: a review of the data
TD-AU-13-002-EN-N
I Acknowledgements
This publication was written by Linda Montanari, Manuela Pasinetti, Danica Thanki and 
Julian Vicente.
About the EMCDDA
The European Monitoring Centre for Drugs and Drug Addiction is the hub of drug-related 
information in Europe. Its mission is to provide the European Union and its Member States 
with ‘factual, objective, reliable and comparable information’ on drugs and drug addiction 
and their consequences. Established in 1993, it opened its doors in Lisbon in 1995, and is 
one of the European Union’s decentralised agencies. The Centre offers policymakers the 
evidence base they need for drawing up drug laws and strategies. It also helps 
professionals and researchers pinpoint best practice and new areas for analysis. 
Related publications
I Prisons and drugs in Europe: the problem and responses, 2012
I Annual report on the state of the drugs problem in Europe, 2010
I Comorbidity: drug use and mental disorders, 2005
These and all other EMCDDA publications are available from  
www.emcdda.europa.eu/publications
Legal notice: The contents of this publication do not necessarily reflect the official opinions of the 
EMCDDA’s partners, the EU Member States or any institution or agency of the European Union.  
More information on the European Union is available on the Internet (europa.eu).
Luxembourg: Publications Office of the European Union
doi:10.2810/20027 I ISBN 978-92-9168-671-1
© European Monitoring Centre for Drugs and Drug Addiction, 2013
Reproduction is authorised provided the source is acknowledged.
This publication is only available in electronic format.
EMCDDA, Praça Europa 1, Cais do Sodré, 1249-289 Lisbon, Portugal
Tel. (351) 211 21 02 00 I info@emcdda.europa.eu 
emcdda.europa.eu I twitter.com/emcdda I facebook.com/emcdda
